SCYB.CN - Scythian Biosciences Corp.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
3.1700
-0.0300 (-0.94%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close3.2000
Open0.0000
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume509,294
Market Cap155.448M
Beta (3Y Monthly)4.14
PE Ratio (TTM)N/A
EPS (TTM)-1.61
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswirelast month

    Scythian Biosciences Announces Name Change to SOL Global Investments Corp.

    The Company’s shareholders approved the name change at a special meeting of shareholders held on September 14, 2018. In connection with the name change, the Company has applied to change its trading symbol on the Canadian Securities Exchange from “SCYB” to “SOL”. The common shares of the Company are expected to begin trading on the Canadian Securities Exchange under the new symbol on or about October 29, 2018.

  • GlobeNewswire2 months ago

    Scythian Biosciences Makes Strategic Investment in Verano™ Holdings with $188 Million USD Transaction

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl:SCCYF) is pleased to announce a USD$88 million investment in Class B units in Verano Holdings, LLC (“Verano”), a private, Delaware organized, vertically integrated, licensed operator of cannabis cultivation, manufacturing and retail facilities across six key U.S. states and Puerto Rico.  Scythian has also agreed to sell a 100% interest in 3 Boys Farms LLC (“3 Boys Farms”), which it will acquire as described below, to Verano in exchange for USD$100 million of Class B units in Verano. All transactions related to 3 Boys Farms are subject to the receipt of all required governmental approvals including from the Florida Department of Health, Office of Medical Marijuana Use (“Florida OMMU”).

  • GlobeNewswire2 months ago

    Scythian Biosciences Applauds the UK Government’s Decision to Legalize Medical Cannabis

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl:SCCYF) applauds the United Kingdom’s decision to allow specialist doctors the option to legally issue prescriptions for cannabis-based medicines when they believe patients could benefit from the treatment. The law change, passed in Parliament yesterday, came after Home Secretary Sajid Javid listened to concerns from parents of children with conditions such as severe epilepsy.

  • GlobeNewswire2 months ago

    Scythian Biosciences Announces Major Milestone in U.S. Expansion

    Chris, Formerly with Incredibles, One of the Industry’s Leading Vape, Extracts and Wellness Companies, Has Nearly Two Decades of Experience in Greenhouse Architecture, Management and Cultivation. TORONTO, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl:SCCYF) today announced the  Florida Department of Health, Office of Medical Marijuana Use (“DOH”) has approved the transfer of 60% of the Equity of 3 Boys Farms, LLC. (“3 Boys Farms”) to CannCure Investments Inc. (“CannCure”) including 3 Boys Farms’ license to operate as a Medical Marijuana Treatment Center in Florida.

  • GlobeNewswire2 months ago

    Scythian Biosciences Announces Intention to Commence Normal Course Issuer Bid to Repurchase up to 5% of its Common Shares

    Scythian Biosciences Corp. (“Scythian” or the “Company”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) announced its intention to commence a normal course issuer bid (“NCIB”), under which the Company may purchase up to 2,451,861 of the Company’s common shares, representing approximately 5% of its issued and outstanding common shares (the “Shares”). The Company is commencing the NCIB because it believes that, from time to time, the market price of its Shares may not fully reflect the underlying value of the Company’s business and future prospects.

  • GlobeNewswire3 months ago

    Scythian Biosciences Announces Execution of Share Purchase Agreement with MMJ International Investments Inc., owner of Argentina-based ABP S.A.

    Scythian Biosciences Corp. (the "Company" or “Scythian”) (CSE:SCYB) (9SB.F) (OTC – Nasdaq Intl: SCCYF) announces that it has entered into a definitive share purchase agreement (the “Purchase Agreement”) with MMJ International Investments Inc. (“MMJ”), a privately-held British Columbia company and all of the shareholders of MMJ, to acquire all of the issued and outstanding common shares of MMJ (the “Acquisition”).  MMJ is the owner of Argentina-based ABP S.A. (“ABP”), a pharmaceutical import and distribution company with a license to import, sell and distribute medical products and derivatives in Argentina. ABP also holds a license to import cannabidiol oil into Argentina. The Purchase Agreement supersedes the previously-announced business combination agreement between Scythian and MMJ to effect the Acquisition.

  • GlobeNewswire3 months ago

    Scythian Biosciences Closes Acquisition of Marigold Projects Jamaica

    Closing Is Key Benchmark in Finalizing Previously Announced $193 Million Sale of Assets in Caribbean and Latin America. Shares to Be Received in Consideration for the Proposed Sale of Assets in Caribbean ...